New technology platforms in the development of vaccines for the future

Vaccine

Volumn 20, Issue SUPPL. 5, 2002, Pages

  Glück, Reinhard ^a   Metcalfe, I C ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

DNA vaccines; IRIVs; Polysaccharide protein conjugates; Recombinant MV vaccines

Indexed keywords

ANTIGEN; CYTOTOXIC AGENT; DNA VACCINE; DOXORUBICAN; HEPATITIS A VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; MACROGOL; MEASLES VACCINE; MUMPS VACCINE; PEPTIDE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; POLYSACCHARIDE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIROSOME; VIRUS GLYCOPROTEIN; VIRUS HEMAGGLUTININ; VIRUS PROTEIN; VIRUS SIALIDASE; VIRUS VACCINE; BACTERIAL VACCINE; VIROSOME VACCINE;

BACTERIUM CARRIER; CONJUGATE; CYTOSOL; DISEASE CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFECT; ESCHERICHIA COLI; GENE CONTROL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; IMMUNOPOTENTIATION; INFLUENZA VIRUS; LISTERIA; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MEASLES VIRUS; MUMPS VIRUS; NONHUMAN; OVARY CARCINOMA; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SALMONELLA; SHIGELLA; T LYMPHOCYTE; TECHNOLOGY; VACCINATION; VIRUS GENE; VIRUS RECOMBINANT; GENETICS; HEPATITIS A; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFLUENZA; MEASLES; METHODOLOGY; PHARMACEUTICS; VIRUS INFECTION;

BACTERIAL VACCINES; HEPATITIS A; HUMANS; IMMUNIZATION; INFLUENZA, HUMAN; MEASLES; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TECHNOLOGY, PHARMACEUTICAL; VACCINES, DNA; VACCINES, VIROSOME; VIRAL VACCINES;

EID: 0037146938     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00513-3     Document Type: Article

References (48)

1. Edelman R. The development and use of vaccine adjuvants. Mol. Biotechnol. 21:2002;129-148.
2. Andersson C., Vasconcelos N.M., Sievertzon M., Haddad D., Liljeqvist S., Berglund P.et al. Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparum antigen Pf332. Scand J. Immunol. 54:2001;117-124.
3. Clements M.L., Betts R.F., Tierney E.L.et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild type virus. J. Clin. Microbiol. 24:1986;157-160.
4. Couch R.B., Keitel W.A., Cate T.R. Improvement of inactivated influenza vaccines. J. Infect. Dis. 176:1997;38-44.
5. Naim J.O., van Oss C.J., Wu W., Giese R.F., Nickerson P.A. Mechanisms of adjuvancy: I-metal oxides as adjuvants. Vaccine. 15:1997;1183-1193.
6. Glück R., Mischler R., Finkel B., Que J.U., Scarpa B., Cryz S.J. Jr Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 344(8916):1994;160-163.
7. Conne P., Gauthey L., Vernet P., Althaus B., Que J.U., Finkel B.et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine. 15:1997;1675-1679.
8. Matlin KS, Reggio H, Helenius A, Simons K. Infectious entry pathway of influenza virus in a canine kidney cell line. J Cell Biol. 1981;Dc. 91:(3 Pt 1):601-13.
9. Glück R. Liposomal presentation of antigens for human vaccines. In: Powell MF, Newman MJ, editors. Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press; 1995. p. 325-45.
10. Taylor A.H., Haberman A.M., Gerard W.et al. Structure-function relationships among highly diverse T cells that recognise a determinant from influenza virus haemagglutinin. J. Exp. Med. 172:1990;1643-1651.
11. Wiedermann G., Kundi M., Ambrosch F. Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Act Trop. 69(2):1998;121-125.
12. Holzer B.R., Hatz C., Schmidt-Sissolak D., Glück R., Althaus B., Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine. 14(10):1996;982-986.
13. Glück R, Cryz Jr. J. IRIV Vaccine delivery. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. New Generation Vaccines. New York: Marcel Dekker Inc.; 1997. p. 247-52.
14. Atlanta C.D.C. Prevention and control of influenza: recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR. 51:2002;1-31.
15. Hu K.F., Lovgren-Bengtsson K., Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug. Deliv. Rev. 51(1/3):2001;149-159.
16. Glück R., Mischler R., Durrer P., Fürer E., Lang A.B., Herzog C.et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181:2000;1129-1132.
17. Glück U., Gebbers J.-O., Glück R. Phase I evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73(35):1999;7780-7786.
18. Herzog C, Durrer P, Lang A, Moser R, Spyr C, Glueck U, Glueck R. Humoral and mucosal immune response in young healthy adults of an intranasal Escherichia coli heat-labile toxin (HLT) adjuvanted compared to a parenteral inactivated virosome-formulated influenza vaccine. In: Proceedings of the 40th ICAAC, 2000 Sep 17-20; Metro Toronto Convention Centre, Ontario, Canada. Poster 2205.
19. McGhee J.R., Kiyono H. New Perspectives in vaccine development: mucosal immunity to infections. Infect Agents Dis. 2:1993;55-73.
20. Holmgren J. Mucosal immunity and vaccination. FEMS Microbiol Immunol. 89:1991;1-10.
21. Zhao J., Takamurs M., Yamaoka A., Odajima Y., Iikura Y. Altered eosinophil levels as a result of viral infection in asthma exacerbation in childhood. Pediatr. Allergy Immunol. 13:2002;47-50.
22. Hunziker I.P., Zurbriggen R., Glück R., Engler O.B., Reichen J., Dai W.J.et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. 38:2001;475-484.
23. Cho J.E., Kim H.S., Ahn W.S., Park Y.S. Enhanced cytotoxicity of doxorubicin encapsulated in liposomes with reconstituted Sendai F-proteins. J. Microencapsul. 18:2001;421-431.
24. Moreno R., Jiang L., Moehle K., Zurbriggen R., Glück R., Robinson J.A.et al. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem. 2:2001;838-843.
25. Pöltl-Frank F., Zurbriggen R., Helg A., Stuart F., Robinson J., Glück R.et al. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide based vaccine. Clin. Exp. Immunol. 117:1999;496-503.
26. Zuckerman A.J., Zuckerman J.N. Prospects for a hepatitis C vaccine. J. Hepatol. 22:1995;97-100.
27. Mastrobattista E., Schoen P., Wilschut J., Crommelin D.J., Storm G. Targeting influenza virosomes to ovarian carcinoma cells. FEBS Lett. 509(1):2001;71-76.
28. Waelti E.R., Glück R. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int J Cancer. 77(5):1998;728-733.
29. Waelti E., Wegmann N., Schwaninger R.et al. Targeting HER-2/neu with antirat neu virosomes for cancer therapy. Cancer Res. 62:2002;437-444.
30. Thalhamer J., Leitner W., Hammerl P., Brtko J. Designing immune responses with genetic immunisation and immunostimulatory DNA sequences. Endocr Regul. 35(3):2001;143-166.
31. Ramsay A.J., Ramshaw I.A., Ada G.L. DNA immunisation. Immunol Cell Biol. 75(4):1997;360-363.
32. Kofta W., Wedrychowicz H. cDNA vaccination against parasitic infections: advantages and disadvantages. Vet. Parasitol. 100(1/2):2001;3-12.
33. Tuteja R. DNA vaccine against malaria: a long way to go. Crit. Rev. Biochem. Mol. Biol. 37(1):2002;29-54.
34. Johnson-Saliba M., Jans D.A. Gene therapy: optimising DNA delivery to the nucleus. Curr. Drug Targets. 2(4):2001;371-399.
35. Cusi M.G., Zurbriggen R., Valassina M., Bianchi S., Durrer P., Valensin P.E.et al. Intranasal immunisation with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology. 277:2000;111-118.
36. Deck R.R., Dewitt C.M., Donnelly J.J., Liu M.A., Ulmer J.B. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine. 15:1997;71-78.
37. Sizamore D.R., Branstrom A.A., Sadoff J.C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science. 270:1995;299-302.
38. Powell RJ, Lewis GK, Hone DM. Introduction of eukaryotic expression cassettes into animal cells using a bacterial vector delivery system. In: Vaccines 96: Molecular Approaches to the Control of Infectious Disease. Cold Spring Harbor Laboratory: Cold Spring Harbor (NY); 1996. p. 183-187.
39. Darji A., Guzman G.A., Gerstel B., Wachholz P., Timmis K.N., Wehland J.et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell. 91:1997;765-775.
40. Dietrich G., Bubert A., Gentschev I., Sokolovic Z., Simm A., Catic A.et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat. Biotechnol. 16:1998;181-185.
41. Pasetti M.F., Anderson R.J., Noriega F.R., Levine M.M., Sztein M.B. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin. Immunol. 92:1999;76-89.
42. Dietrich G., Gentschev I., Hess J., Ulmer J.B., Kaufmann S., Goebel W. Delivery of DNA vaccines by attenuated intracellular bacteria. Immunol. Today. 20:1999;251-253.
43. Schneider U., Bullough F., Vongspunsawad S., Russell S.J., Cattaneo R. Recombinant measles viruses efficeintly entering cells through targeted receptors. J. Virol. 74:2000;9928-9936.
44. Singh M., Cattaneo R., Billeter M.A. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J. Virol. 73:1999;4823-4828.
45. Wang Z., Hangartner L., Cornu T.I., Martin L.R., Zuniga A., Billeter M.A.et al. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine. 19:2001;2329-2336.
46. Grote D., Russell S.J., Cornu T.I., Cattaneo R., Vile R., Poland G.A.et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood. 97:2001;3746-3754.
47. Lang A.B., Schaad U.B., Rüdeberg A., Wedgwood J., Que J.U., Fürer E.et al. Effect of high affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunisation on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J. Pediatr. 127:1995;711-717.
48. Schaad U.B., Lang A.B., Wedgwood J., Rüdeberg A., Que J.U., Fürer E.et al. Safety and immunogenicity of Pseudomonas aeruginosa polyvalent conjugate A vaccine in cystic fibrosis. Lancet. 338:1991;1236-1237.